RT Journal Article
SR Electronic
T1 Venous Thromboembolism in Ambulatory Covid-19 patients: Clinical and Genetic Determinants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.22.22272748
DO 10.1101/2022.03.22.22272748
A1 Xie, JQ
A1 Prats-Uribe, A
A1 Feng, Q
A1 Wang, YH
A1 Gill, D
A1 Paredes, R
A1 Prieto-Alhambra, D
YR 2022
UL http://medrxiv.org/content/early/2022/03/22/2022.03.22.22272748.abstract
AB Background Substantial evidence suggests that severe Covid-19 leads to an increased risk of Venous Thromboembolism (VTE). We aimed to quantify the risk of VTE associated with ambulatory Covid-19, study the potential protective role of vaccination, and establish key clinical and genetic determinants of post-Covid VTE.Methods We analyzed a cohort of ambulatory Covid-19 patients from UK Biobank, and compared their 30-day VTE risk with propensity-score-matched non-infected participants. We fitted multivariable models to study the associations between age, sex, ethnicity, socio-economic status, obesity, vaccination status and inherited thrombophilia with post-Covid VTE.Results Overall, VTE risk was nearly 20-fold higher in Covid-19 vs matched non-infected participants (hazard ratio [HR] 19.49, 95% confidence interval [CI] 11.50 to 33.05). However, the risk was substantially attenuated amongst the vaccinated (HR: 2.79, 95% CI 0.82 to 9.54). Older age, male sex, and obesity were independently associated with higher risk, with adjusted HRs of 2.00 (1.61 to 2.47) per 10 years, 1.66 (1.28 to 2.15), and 1.85 (1.29 to 2.64), respectively. Further, inherited thrombophilia led to an HR 2.05, 95% CI 1.15 to 3.66.Conclusions Ambulatory Covid-19 was associated with a striking 20-fold increase in incident VTE, but no elevated risk after breakthrough infection in the fully vaccinated. Older age, male sex, and obesity were clinical determinants of Covid-19-related VTE. Additionally, inherited thrombophilia doubled risk further, comparable to the effect of 10-year ageing. These findings reinforce the need for vaccination, and call for targeted strategies to prevent VTE during outpatient care of Covid-19.Competing Interest StatementProf Prieto-Alhambra that his research group has received grants and advisory or speaker fees from Amgen, Astellas, AstraZeneca, Chiesi-Taylor, Johnson & Johnson, and UCB; and that Janssen, on behalf of Innovative Medicines Initiative funded European Health Data Evidence Network and European Medical Information Framework consortiums and Synapse Management Partners, have supported training programs, open to external participants, organized by his department. DG is employed part time by Novo Nordisk. Roger Paredes has participated in advisory boards for Gilead, MSD, ViiV Healthcare, Theratechnologies and Lilly. His institution has received research support from Gilead, MSD, and ViiV Healthcare.Funding StatementMr Xie is funded through Jardine-Oxford Graduate Scholarship and a titular Clarendon Fund Scholarship. DG is supported by the British Heart Foundation Research Centre of Excellence (RE/18/4/34215) at Imperial College London and by a National Institute for Health Research Clinical Lectureship (CL-2020-16-001) at St. George's, University of London. Prof Prieto-Alhambra is funded through an NIHR Senior Research Fellowship (grant SRF-2018-11-ST2-004), and received partial support from the Oxford NIHR Biomedical Research Centre. APU has received funding from the Medical Research Council (MRC) [MR/K501256/1, MR/N013468/1].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesBonafide researchers can apply to use the UK Biobank dataset by registering and applying at http://ukbiobank.ac.uk/register-apply/. The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request